Ensysce Biosciences, Inc. · NASDAQ:ENSC
Ensysce Biosciences — Investor Presentation (August 2026)
23 slides from Ensysce Biosciences's investor presentation, August 2026
Slide 1: NASDAQ: ENSC Investor Presentation Aug 2026
NASDAQ: ENSC Investor Presentation Aug 2026
Slide 2: Forward-looking statements
Cy CyBiopharma Biopharma Investor Presentation | Aug 2026 Ensysce’s PF614, PF614-MPAR and nafamostat are currently in clinical trials and pre-clinical studies. Cy’s CY200 is in clinical developments. Accordingly, PF614, PF-614-MPAR and CY200 have the risks and uncertainties inherent in any drug in t
Slide 3: Cy Biopharma investment highlights
Cy Biopharma Investor Presentation | Aug 2026 Clinical-stage – ‘Next generation opioids’ - disrupting analgesia using Clinical-stage - addressing the root cause of chronic pain through transformative trypsin-controlled chemistry. central nervous system modulation with new class of small molecule the
Slide 4: Neuroscience and Pain
Cy Biopharma Investor Presentation | Aug 2026 Neuroscience and Pain Program Therapeutic Target Discovery Phase 1 Phase 2 Phase 3 PF614 Pain with abuse protection TAAP-Oxycodone FDA Fast Track PF614-MPAR Pain with overdose protection TAAP-MPAR-Oxycodone FDA Breakthrough Therapy PF8001 ADHD - Immediat
Slide 5: CY200 Neural Reset
CY200 Neural Reset A new class for pain Serotonergic modulation of neural networks FDA Orphan Drug Designation 2026 *ischysogenic/ From Greek ischys ‘strength’ + genic ‘producing, giving rise to’
Slide 6: CY Therapy Overview
Cy Biopharma Investor Presentation | Aug 2026 CY Therapy Overview Page 6
Slide 7: CY200 Mechanisms of action
Cy Biopharma Investor Presentation | Aug 2026 CY200 Mechanisms of action Multi-tryptamine therapy - Neural Reset 5HT2 Activation improves Pain/ Mood Synaptic remodeling Reduced central sensitization Reduced pain chronification Page 7
Slide 8: CRPS – Refractory Severe Chronic Pain
Cy Biopharma Investor Presentation | Aug 2026 CRPS – Refractory Severe Chronic Pain 200,000 30% No Americans with CRPS2-4 Of sufferers approved unable to work3 therapy Current treatment options - $30,000-150,0001 Page 8
Slide 9: Latest Clinical data in CRPS
Cy Biopharma Investor Presentation | Aug 2026 Latest Clinical data in CRPS Cy Biopharma sponsored studies generated clinical data used for FDA orphan drug designation as well as independent academic work. Innovative POC – observational study ongoing Observed effect in a POC subject - > 2.5 month
Slide 10: CY200/201 Development Plan
Cy Biopharma Investor Presentation | Aug 2026 CY200/201 Development Plan Page 10
Slide 11: CY Differentiated NCE Pipeline
Cy Biopharma Investor Presentation | Aug 2026 CY Differentiated NCE Pipeline Page 11
Slide 12: Cy Biopharma
Cy Biopharma Investor Presentation | Aug 2026 Page 12
Slide 13: TAAP and MPAR
Cy Biopharma Investor Presentation | Aug 2026 TAAP TM Trypsin-Activated Abuse Protection* MPAR ® Multi-Pill Abuse Resistance: Combination Product for Overdose Protection * PROTECTIVE Trypsin TURNS ON RELEASE. TURNS OFF RELEASE only with overdose. SMART CONTROLLABLE Chemically engineered to control T
Slide 14: Powerful Analgesia + Overdose protection
Cy Biopharma Powerful Analgesia + Overdose protection TAAP Oxycodone combination product Breakthrough Therapy Designation Grant by FDA January 2024
Slide 15: Pre-clinical MPAR support data
CyCyBiopharma Biopharma Investor Presentation | Aug 2026 Investor Presentation | Aug 2026 PRE-CLINICAL MPAR SUPPORT DATA Blocks Activation of PF614 and Oxycodone Release if Overdosed Combination product of PF614 with an V ultrapotent trypsin inhibitor, nafamostat Taken at prescribed doses there is n
Slide 16: Trypsin controlled opioid release
Cy Biopharma Investor Presentation | Aug 2026 Clinical Data Demonstrating Oral Overdose Protection Achievable PF614 alone no MPAR® overdose protection PF614-MPAR 25 mg with MPAR® overdose protection PF614-MPAR with overdose protection [1] [2] [3] [4] [5] [6] [7] [8] PF614 mg PF614 (mg) or PF614-MPAR
Slide 17: Clinical Development for Overdose Protection
Cy Biopharma Investor Presentation | Aug 2026 Clinical Development for Overdose Protection 2026 OUTCOME SIGNIFICANCE Confirm overdose protection followed by MAD PF614-MPAR-102 Continue Phase 1b SAD 100 mg dose and food effect study to support Type B FDA meeting PF614-MPAR regulatory FDA to discuss ‘
Slide 18: Expanded Opportunities
Cy Biopharma Expanded Opportunities
Slide 19: TAAP Modification Attributes
Cy Biopharma Investor Presentation | Aug 2026 Improving Drug Delivery and Lifecycle Management OPPORTUNITY TAAP MODIFICATION ATTRIBUTES Reaches the gastrointestinal tract/epithelial Our TAAP platform enables new chemical entity cells intact (NCE) solutions that allow us to obtain new patents and ext
Slide 20: Experienced Management
Ensysce’ Cy Biopharma EXPERIENCED MANAGEMENT
Slide 21: Highly Motivated, Experienced Team with Proven Record
Cy Biopharma Investor Presentation | Aug 2026 Highly Motivated, Experienced Team with Proven Record D. LYNN KIRKPATRICK, PHD DAVID HUMPHREY, CPA JAMES MORRISON Chief Executive Officer Chief Financial Officer Chief Operating Officer Co-founded 2 start up companies Extensive experience in entrepre
Slide 22: Pain, Addiction and Abuse Expertise
Cy Biopharma Investor Presentation | Aug 2026 Pain, Addiction and Abuse Expertise DR. LYNN WEBSTER DR. JEFFREY GUDIN DR. RICHARD DART DR. WILLIAM SCHMIDT DR. RICHARD LANGFORD Dr. Webster has dedicated more than three Dr. Gudin is Faculty Dept of Anesthesiology/Pain Dr. Dart, former Director of Rocky
Slide 23: Contact
Cy Biopharma SHANNON DEVINE MZ North America 203-741-8811 ENSC@mzgroup.us 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037 W W W. E N S Y S C E . C O M
Ensysce Biosciences — Investor Presentation (August 2026) on 6ix